Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:YMTX

Yumanity Therapeutics (YMTX) Stock Price, News & Analysis

Yumanity Therapeutics logo

About Yumanity Therapeutics Stock (NASDAQ:YMTX)

Key Stats

Today's Range
N/A
50-Day Range
$0.56
$1.89
52-Week Range
N/A
Volume
6,790 shs
Average Volume
473,083 shs
Market Capitalization
$7.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive YMTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Yumanity Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

YMTX Stock News Headlines

JSPR Jasper Therapeutics, Inc.
Cara Therapeutics Inc CARA
What if your job didn’t matter — and neither did China’s chip ban?
If you’ve been watching the headlines lately…You’ve seen how Nvidia and AMD just got the green light to resume chip exports to China. That news sent their stocks flying. But here’s the truth: By the time the market reacts to big news, most traders are too late.tc pixel
Yumanity Therapeutics Inc.
See More Headlines

YMTX Stock Analysis - Frequently Asked Questions

Yumanity Therapeutics, Inc. (NASDAQ:YMTX) announced its earnings results on Thursday, August, 12th. The company reported ($1.03) earnings per share for the quarter, missing analysts' consensus estimates of ($0.84) by $0.19. The business had revenue of $2.11 million for the quarter, compared to the consensus estimate of $2.27 million. Yumanity Therapeutics had a negative net margin of 660.61% and a negative trailing twelve-month return on equity of 263.34%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Yumanity Therapeutics investors own include NIO (NIO), Arch Therapeutics (ARTH), Aytu BioPharma (AYTU), Clarus Therapeutics (CRXTQ), Ford Motor (F), Novavax (NVAX) and Sorrento Therapeutics (SRNE).

Company Calendar

Last Earnings
8/12/2021
Today
10/09/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:YMTX
CIK
1445283
Fax
N/A
Employees
40
Year Founded
2014

Profitability

EPS (Trailing Twelve Months)
($3.00)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$39.50 million
Net Margins
-660.61%
Pretax Margin
-660.61%
Return on Equity
-263.34%
Return on Assets
-107.08%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.21
Quick Ratio
2.21

Sales & Book Value

Annual Sales
$4.84 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.28 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
10,856,000
Free Float
9,504,000
Market Cap
$7.46 million
Optionable
Not Optionable
Beta
0.32

Social Links

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:YMTX) was last updated on 10/10/2025 by MarketBeat.com Staff
From Our Partners